Autolus Therapeutics Plc (AUTL)
1.54
-0.04
(-2.53%)
USD |
NASDAQ |
Oct 23, 16:00
1.535
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Enterprise Value : 574.58M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 574.58M |
| October 22, 2026 | 585.22M |
| October 21, 2026 | 595.87M |
| October 20, 2026 | 606.52M |
| October 19, 2026 | 587.88M |
| October 16, 2026 | 590.55M |
| October 15, 2026 | 622.49M |
| October 14, 2026 | 614.50M |
| October 13, 2026 | 595.87M |
| October 12, 2026 | 627.81M |
| October 09, 2026 | 646.44M |
| October 08, 2026 | 635.79M |
| October 07, 2026 | 646.44M |
| October 06, 2026 | 641.12M |
| October 05, 2026 | 651.76M |
| October 02, 2026 | 638.46M |
| October 01, 2026 | 657.09M |
| September 30, 2026 | 681.04M |
| September 29, 2026 | 659.75M |
| September 28, 2026 | 659.75M |
| September 25, 2026 | 658.42M |
| September 24, 2026 | 673.06M |
| September 23, 2026 | 683.70M |
| September 22, 2026 | 705.00M |
| September 21, 2026 | 681.04M |
| Date | Value |
|---|---|
| September 18, 2026 | 681.04M |
| September 17, 2026 | 675.72M |
| September 16, 2026 | 662.41M |
| September 15, 2026 | 667.73M |
| September 14, 2026 | 681.04M |
| September 11, 2026 | 665.07M |
| September 10, 2026 | 686.36M |
| September 09, 2026 | 705.00M |
| September 08, 2026 | 726.29M |
| September 04, 2026 | 760.89M |
| September 03, 2026 | 774.20M |
| September 02, 2026 | 760.89M |
| September 01, 2026 | 779.52M |
| August 31, 2026 | 790.17M |
| August 28, 2026 | 787.51M |
| August 27, 2026 | 792.83M |
| August 26, 2026 | 784.84M |
| August 25, 2026 | 814.12M |
| August 24, 2026 | 787.51M |
| August 21, 2026 | 806.14M |
| August 20, 2026 | 819.45M |
| August 19, 2026 | 840.74M |
| August 18, 2026 | 774.20M |
| August 17, 2026 | 771.54M |
| August 14, 2026 | 736.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Bicycle Therapeutics Plc | -316.00M |
| Biodexa Pharmaceuticals Plc | -- |
| argenx SE | 54.00B |
| NuCana Plc | -20.75M |
| Mereo BioPharma Group Plc | 15.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -39.18M |
| Revenue (Quarterly) | 45.77M |
| Total Expenses (Quarterly) | 84.95M |
| EPS Diluted (Quarterly) | -0.1472 |
| Gross Profit Margin (Quarterly) | 55.20% |
| Profit Margin (Quarterly) | -85.60% |
| Earnings Yield | -68.19% |
| Normalized Earnings Yield | -68.13 |